Post-discharge pharmacotherapy in people with atrial fibrillation hospitalized for acute myocardial infarction: an Australian cohort study 2018–22

医学 普拉格雷 替卡格雷 氯吡格雷 心房颤动 华法林 中止 阿司匹林 心肌梗塞 内科学 队列 冲程(发动机) 抗血栓 心脏病学 机械工程 工程类
作者
Claire T. Deakin,Juliana de Oliveira Costa,David Brieger,Jialing Lin,Andrea L. Schaffer,Michael Kidd,Sallie‐Anne Pearson,Michael O. Falster
出处
期刊:European Heart Journal - Quality of Care and Clinical Outcomes [Oxford University Press]
被引量:1
标识
DOI:10.1093/ehjqcco/qcae068
摘要

Abstract Background Dual antiplatelet therapy with P2Y12 inhibitors (P2Y12i) and aspirin following acute myocardial infarction (AMI) prevents future ischaemic events. People with atrial fibrillation (AF) also require oral anticoagulants (OAC), increasing bleeding risk. Guidelines recommend post-discharge prescribing of direct OAC with clopidogrel and discontinuation of P2Y12i after 12 months, but little is known about use in clinical practice. Aim To describe post-discharge use of OACs and P2Y12i in people with AF and a history of OAC use hospitalized for AMI. Methods and results We identified 1330 people hospitalized for AMI with a diagnosis of AF and history of OAC use in New South Wales, Australia, July 2018–June 2020. We identified three aspects of post-discharge antithrombotic medicine use with possible safety implications: (1) not being dispensed OACs; (2) dispensing OAC and P2Y12i combinations associated with increased bleeding (involving warfarin, ticagrelor, or prasugrel); and (3) P2Y12i use longer than 12 months. After discharge, 74.3% of people were dispensed an OAC, 45.4% were dispensed a P2Y12i, and 35.8% were dispensed both. People with comorbid heart failure or cancer were less likely to receive OACs. Only 11.2% of people who dispensed both an OAC and P2Y12i received combinations associated with increased bleeding; this was more common among people with chronic kidney disease or prior warfarin or statin use. A total of 44.6% of people dispensed both medicines continued P2Y12i for over 12 months; this was more common in people who received a revascularization or lived in areas of social disadvantage. Conclusion We identified potential gaps in pharmacotherapy, including underuse of recommended therapies at discharge, use of combinations associated with increased bleeding, and P2Y12i use beyond 12 months. Prescribing vigilance across both hospital and community care is required.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
123发布了新的文献求助10
刚刚
guard发布了新的文献求助10
刚刚
Ttttsyu发布了新的文献求助10
刚刚
2秒前
迷人的天抒应助倪妮采纳,获得10
3秒前
5秒前
6秒前
与落发布了新的文献求助10
6秒前
科研通AI6.3应助万安安采纳,获得10
6秒前
123完成签到,获得积分20
7秒前
8秒前
dyh发布了新的文献求助10
8秒前
蓝天发布了新的文献求助10
8秒前
CipherSage应助好好采纳,获得10
8秒前
拜了个拜完成签到,获得积分10
10秒前
tmobiusx完成签到,获得积分10
11秒前
星辰大海应助糖豆豆采纳,获得10
12秒前
酷波er应助Dinah采纳,获得50
13秒前
emmm发布了新的文献求助10
13秒前
笨笨西牛发布了新的文献求助10
13秒前
14秒前
14秒前
liuzhuohao应助Bruial采纳,获得10
15秒前
都会完成签到 ,获得积分0
15秒前
Sky完成签到,获得积分10
16秒前
思源应助学习采纳,获得10
17秒前
18秒前
yxy发布了新的文献求助10
18秒前
大个应助maopf采纳,获得10
19秒前
CodeCraft应助耍酷碧菡采纳,获得10
20秒前
万安安发布了新的文献求助10
21秒前
好好发布了新的文献求助10
21秒前
22秒前
wangmudan应助与落采纳,获得10
23秒前
25秒前
不知道是谁完成签到,获得积分10
25秒前
27秒前
Owen应助蓝天采纳,获得10
28秒前
科研通AI6.2应助emmm采纳,获得10
29秒前
Dinah发布了新的文献求助50
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场现状调查及投资机会研判报告 1000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
适配Micro-LED色转换的高兼容性量子点负性光刻胶制备与工艺研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7315688
求助须知:如何正确求助?哪些是违规求助? 8931712
关于积分的说明 18933073
捐赠科研通 6975793
什么是DOI,文献DOI怎么找? 3213933
关于科研通互助平台的介绍 2381874
邀请新用户注册赠送积分活动 2192518